seladelpar Report issue

Small molecule Experimental
AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
Seladelpar is a PPARδ receptor agonist that is being investigated for drug use by Metabolex. According to a press release they are examining its potential use for the treatment of dyslipidemia, metabolic syndrome, type 2 diabetes, and non-alcoholic steatohepatitis (NASH). The compound was licensed from Janssen Pharmaceutica NV.   Wikipedia

Chemistry

  • SMILES: CCO[C@H](COc1ccc(cc1)C(F)(F)F)CSc2ccc(OCC(=O)O)c(C)c2
  • InChIKey: JWHYSEDOYMYMNM-QGZVFWFLSA-N
  • Mol. Mass: 444.47
  • ALogP: 5.05
  • ChEMBL Molecules:
    seladelpar  
    mbx-8025  
More Chemistry

Pharmacology

Alternative names

(2-methyl-4-(5-methyl-2-(4-trifluoromethyl-phenyl)-2h-(1,2,3)triazol-4-ylmethylsulfanyl)phenoxy)acetic acid | mbx-8025 | rwj-800025 | seladelpar

Organizations (1)

Research & Development (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (7)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (7)


 

Cholangitis, Sclerosing (Phase 2)

Homozygous Familial Hypercholesterolemia (Phase 2)

Hyperlipidemias (Phase 2)

Liver Cirrhosis (Phase 2)

Liver Cirrhosis, Biliary (Phase 3)

Liver Diseases (Phase 1)

Non-alcoholic Fatty Liver Disease (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 11
  • # of Trial Organizations: 1

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue